Boundless Bio, Inc.

What they do

Boundless Bio is a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology to treat oncogene-amplified cancers. Its lead candidate, BBI-940, is an oral, selective kinesin degrader (ecDTx) being evaluated in the first-in-human KOMODO-1 trial for ER+/HER2- breast cancer and TNBC-LAR. The company has no approved products and generates no revenue.

Revenue drivers

• BBI-940 (clinical-stage) — Potential first-in-class oral kinesin degrader; no commercial revenue; value depends on clinical success of KOMODO-1 trial.

Recent performance

For Q1 2026, net loss was $13.6 million, compared to $15.8 million in Q1 2025. R&D expenses were $9.7 million (down from $12.1 million) and G&A expenses were $4.7 million (down from $5.2 million). Cash and short-term investments totaled $92.8 million as of March 31, 2026, which management expects to fund operations into the second half of 2028. Full-year net losses were $-49.4M (2023), $-65.4M (2024), and $-58.2M (2025). As of June 30, 2026, cash and equivalents were $20.2 million, with total assets of $73.7 million and shareholder equity of $66.0 million.

Strategy

The company is advancing BBI-940 through KOMODO-1, a first-in-human trial in ER+/HER2- breast cancer (post CDK4/6 inhibitor) and TNBC-LAR. It presented AACR 2026 data showing kinesin degradation induces ecDNA mis-segregation and tumor regression across multiple models. Management intends to use existing cash to reach clinical proof-of-concept, and has been actively managing portfolio priorities and evaluating strategic collaborations, though recent 8-Ks indicate a material agreement and a termination of an agreement, suggesting potential restructuring.

Risks

• Clinical development risk — BBI-940 is in first-in-human testing; no safety or efficacy data in patients has been reported yet.
• Financing runway — Cash and equivalents dropped from $92.8 million (March 2026) to $20.2 million (June 2026), implying significant burn and a need for additional capital.
• No revenue — The company has no approved products or revenue; relies entirely on equity financing, which may be dilutive.
• Corporate events — Recent 8-Ks indicate a material agreement, a termination of a material agreement, and a change in control, which could signal strategic or operational disruption.

Outlook

Management expects KOMODO-1 enrollment to continue and initial safety and efficacy proof-of-concept data within the existing cash runway. The company reiterates a cash runway into the second half of 2028, though this is based on Q1 cash position and assumes no unexpected costs. Upcoming milestones include further development of BBI-940 and potential strategic collaborations.